Literature DB >> 3402593

Monensin inhibits the expression of sucrase-isomaltase in Caco-2 cells at the mRNA level.

I Chantret1, G Trugnan, E Dussaulx, A Zweibaum, M Rousset.   

Abstract

Using L-[35S]methionine labeling, SDS-PAGE and Northern blot analysis of sucrase-isomaltase mRNA, two different concentrations of monensin were used to delineate in Caco-2 cells the effect of the drug on the conversion of the high mannose to the complex form of sucrase-isomaltase from its dual effect on the biosynthesis of the enzyme and on the rate of glucose consumption. At 0.1 microM the drug has no effect on the rate of glucose consumption and, although it inhibits the conversion of the high mannose to the complex form of the enzyme, it has no effect on the level of sucrase-isomaltase mRNA and on the amount of neosynthesized enzyme. At 1 microM, in addition to its inhibiting effect on the maturation of the enzyme, monensin provokes concomitantly an increase in the rate of glucose consumption and a decrease in the level of sucrase-isomaltase mRNA and in the amount of neosynthesized enzyme. All these effects are reversible within 48 h after removal of the drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3402593     DOI: 10.1016/0014-5793(88)81246-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Sequence of the complete cDNA and the 5' structure of the human sucrase-isomaltase gene. Possible homology with a yeast glucoamylase.

Authors:  I Chantret; M Lacasa; G Chevalier; J Ruf; I Islam; N Mantei; Y Edwards; D Swallow; M Rousset
Journal:  Biochem J       Date:  1992-08-01       Impact factor: 3.857

2.  Decrease of mRNA levels and biosynthesis of sucrase-isomaltase but not dipeptidylpeptidase IV in forskolin or monensin-treated Caco-2 cells.

Authors:  D Darmoul; L Baricault; C Sapin; I Chantret; G Trugnan; M Rousset
Journal:  Experientia       Date:  1991-12-01

Review 3.  Adaptation of intestinal nutrient transport in health and disease. Part II.

Authors:  A B Thomson; G Wild
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

4.  Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell growth and glucose consumption.

Authors:  L Mahraoui; A Rodolosse; A Barbat; E Dussaulx; A Zweibaum; M Rousset; E Brot-Laroche
Journal:  Biochem J       Date:  1994-03-15       Impact factor: 3.857

Review 5.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

6.  Human enterocyte (Caco-2) migration is modulated in vitro by extracellular matrix composition and epidermal growth factor.

Authors:  M D Basson; I M Modlin; J A Madri
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

7.  A limited upstream region of the human sucrase-isomaltase gene confers glucose-regulated expression on a heterologous gene.

Authors:  A Rodolosse; I Chantret; M Lacasa; G Chevalier; A Zweibaum; D Swallow; M Rousset
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

8.  Dystroglycan receptor is involved in integrin activation in intestinal epithelia.

Authors:  Adel Driss; Laetitia Charrier; Yutao Yan; Vivienne Nduati; Shanthi Sitaraman; Didier Merlin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-12-15       Impact factor: 4.052

9.  Clonal analysis of sucrase-isomaltase expression in the human colon adenocarcinoma Caco-2 cells.

Authors:  J F Beaulieu; A Quaroni
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

10.  Rotavirus infection reduces sucrase-isomaltase expression in human intestinal epithelial cells by perturbing protein targeting and organization of microvillar cytoskeleton.

Authors:  N Jourdan; J P Brunet; C Sapin; A Blais; J Cotte-Laffitte; F Forestier; A M Quero; G Trugnan; A L Servin
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.